IQVIA's annual report on US drug usage and spending trends dropped this week and boy, is it a doozy. Not surprisingly, obesity drugs figure prominently, thanks to growth in the use of GLP-1s. (And, this is before new data on the broader health value of the class emerged.) Also to be expected, growth in list prices outpaced net prices, as manufacturers paid more to ensure drugs – especially in competitive classes like immunology – made it onto payers’ formularies.
read full article ›Important milestone for sickle cell gene therapies, patients, and the two manufacturers (bluebird bio and Vertex Pharmaceuticals) developing these innovative therapies.
read full article ›https://www.linkedin.com/posts/real-endpoints_from-price-controls-to-robust-public-conversation-activity-7192243813153701890-NdPi?utm_source=share&utm_medium=member_desktop
read full article ›In case you missed it, a team from Institute for Clinical and Economic Review (ICER), Program on Regulation, Therapeutics, and Law (PORTAL), and Tufts University's Center for the Evaluation of Value and Risk in Health has an important point of view in Health Affairs on how to create an hashtag#IRA price negotiation process that is credible, transparent, and inclusive of relevant stakeholders.
read full article ›In an op-ed published in BioCentury Inc. May 14, Gigi Hirsch of NEWDIGS Initiative at Tufts Medical Center and Jane F. Barlow, MD, MPH, MBA of Real Endpoints make the case that the only way to have our cake (medical innovation) and to be able to eat it (afford the innovation) is to increase health efficiency – that is, capturing the full value of medical products.
read full article ›For the Real Endpoints team, Asembia Day 2 was chock-a-block with 1:1 conversations, panel discussions, and demos of RE Assist, our AI-based platform providing real-time intel of available financial support for patients. Caught in action: Susan Raiola explaining how RE Assist helps solve the Medicare copay dilemma; and Jeff Berkowitz, seen here with Bruce Japsen and Amazon's Laura Jensen, following a spirited panel discussion on the future of digital health, telehealth, and pharmacy.
read full article ›Asembia is hopping. Meetings are appropriately fueled by bread and chocolate - you know the staff of life! Some hot takes from the field,
read full article ›Healthcare information focused on the intersection of payers and product companies.
read full article ›